{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:48:51Z","timestamp":1792900131403,"version":"4.5.0"},"reference-count":80,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the emergence and development of antiangiogenic therapies to eliminate bleeding telangiectasias and achieve hemostasis. This progress is reflected in recent clinical recommendations published in the Second International Guidelines for the Diagnosis and Treatment of HHT, in which systemic therapies including antiangiogenics and antifibrinolytics are now recommended as standard treatment options for bleeding. This review highlights the new recommendations especially relevant to hematologists in managing bleeding, anticoagulation, and anemia in patients with HHT.<\/jats:p>","DOI":"10.1182\/blood.2020008739","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T22:58:15Z","timestamp":1605049095000},"page":"888-895","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":84,"title":["Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[{"name":"Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2022041419424788200_B1","first-page":"769","article-title":"Epistaxis as an indication of impaired nutrition and of degeneration of the vascular system","volume":"1","author":"Sutton","year":"1864","journal-title":"Med Mirror"},{"key":"2022041419424788200_B2","first-page":"731","article-title":"\u00c9pistaxis r\u00e9p\u00e9t\u00e9es chez un sujet porteur de petits angiomes cutan\u00e9s et muqueux [Repeated epistaxis in a subject with small skin and mucous angiomas]","volume":"13","author":"Rendu","year":"1896","journal-title":"Bull Mem Soc Med Hop Paris"},{"issue":"4935","key":"2022041419424788200_B3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"issue":"2","key":"2022041419424788200_B4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","article-title":"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells","volume":"161","author":"Ferrara","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2022041419424788200_B5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"Cirulli","year":"2003","journal-title":"Acta Haematol"},{"key":"2022041419424788200_B6","first-page":"M20","article-title":"Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"issue":"9","key":"2022041419424788200_B7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1288\/00005537-199109000-00008","article-title":"The natural history of epistaxis in hereditary hemorrhagic telangiectasia","volume":"101","author":"AAssar","year":"1991","journal-title":"Laryngoscope"},{"issue":"9","key":"2022041419424788200_B8","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist\u2019s perspective","volume":"103","author":"Kritharis","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2022041419424788200_B9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia","volume":"48","author":"Faughnan","year":"2011","journal-title":"J Med Genet"},{"issue":"9","key":"2022041419424788200_B10","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease","volume":"12","author":"Gaillard","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2022041419424788200_B11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study","volume":"134","author":"Geisthoff","year":"2014","journal-title":"Thromb Res"},{"issue":"23","key":"2022041419424788200_B12","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1161\/CIRCULATIONAHA.117.033062","article-title":"Decreased Expression of Vascular Endothelial Growth Factor Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2","volume":"138","author":"Thalgott","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"2022041419424788200_B13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10456-014-9436-3","article-title":"VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2","volume":"17","author":"Han","year":"2014","journal-title":"Angiogenesis"},{"issue":"4","key":"2022041419424788200_B14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat Med"},{"issue":"22","key":"2022041419424788200_B15","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.4103\/0366-6999.169068","article-title":"Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model","volume":"128","author":"Peng","year":"2015","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"2022041419424788200_B16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0194599817700573","article-title":"Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study","volume":"157","author":"Fang","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"11","key":"2022041419424788200_B17","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study","volume":"2","author":"Invernizzi","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"2022041419424788200_B18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4193\/Rhino14.289","article-title":"Follow-up of Thalidomide treatment in patients with Hereditary Haemorrhagic Telangiectasia","volume":"53","author":"Hosman","year":"2015","journal-title":"Rhinology"},{"issue":"1","key":"2022041419424788200_B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4274\/tjh.galenos.2018.2018.0190","article-title":"Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life","volume":"36","author":"Baysal","year":"2019","journal-title":"Turk J Haematol"},{"issue":"2","key":"2022041419424788200_B20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al-Samkari","year":"2019","journal-title":"J Intern Med"},{"issue":"4","key":"2022041419424788200_B21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"issue":"2","key":"2022041419424788200_B22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"2022041419424788200_B23","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.2016.11387","article-title":"Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial","volume":"316","author":"Dupuis-Girod","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"2022041419424788200_B24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial","volume":"316","author":"Whitehead","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"2022041419424788200_B25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hed.23655","article-title":"Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial","volume":"37","author":"Riss","year":"2015","journal-title":"Head Neck"},{"issue":"6","key":"2022041419424788200_B26","doi-asserted-by":"crossref","first-page":"E313","DOI":"10.1002\/ajh.24367","article-title":"Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding","volume":"91","author":"Epperla","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"2022041419424788200_B27","first-page":"242","article-title":"Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series","volume":"57","author":"Rosenberg","year":"2019","journal-title":"Rhinology"},{"issue":"11","key":"2022041419424788200_B28","doi-asserted-by":"crossref","first-page":"e0188943","DOI":"10.1371\/journal.pone.0188943","article-title":"Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients","volume":"12","author":"Guilhem","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"2022041419424788200_B29","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"2022041419424788200_B30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2500\/ar.2014.5.0091","article-title":"Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia","volume":"5","author":"Thompson","year":"2014","journal-title":"Allergy Rhinol (Providence)"},{"issue":"11","key":"2022041419424788200_B31","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1002\/ajh.24878","article-title":"Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia","volume":"92","author":"Chavan","year":"2017","journal-title":"Am J Hematol"},{"key":"2022041419424788200_B32","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study [published online ahead of print 16 July 2020]","author":"Al-Samkari","journal-title":"Haematologica"},{"issue":"5","key":"2022041419424788200_B33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lary.25669","article-title":"The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia","volume":"126","author":"Yin","year":"2016","journal-title":"Laryngoscope"},{"issue":"6","key":"2022041419424788200_B34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1538-7836.2007.02531.x","article-title":"Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers","volume":"5","author":"Sabb\u00e0","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2022041419424788200_B35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.meg.0000252633.88419.04","article-title":"Assessment of intestinal vascular malformations in patients with hereditary hemorrhagic teleangiectasia and anemia","volume":"19","author":"van Tuyl","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"2022041419424788200_B36","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.gie.2009.11.004","article-title":"High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and\/or severe anemia","volume":"71","author":"Gr\u00e8ve","year":"2010","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"2022041419424788200_B37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/gim.2013.62","article-title":"Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectasia and correlation with their genotypes","volume":"16","author":"Canzonieri","year":"2014","journal-title":"Genet Med"},{"issue":"2","key":"2022041419424788200_B38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1572-0241.2000.01792.x","article-title":"Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia","volume":"95","author":"Kjeldsen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2022041419424788200_B39","doi-asserted-by":"crossref","first-page":"4798425","DOI":"10.1155\/2018\/4798425","article-title":"Impact of Age on Outcomes in Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia","volume":"2018","author":"Iyer","year":"2018","journal-title":"Adv Hematol"},{"issue":"1","key":"2022041419424788200_B40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00277-014-2169-y","article-title":"The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey","volume":"94","author":"Zaffar","year":"2015","journal-title":"Ann Hematol"},{"key":"2022041419424788200_B41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2016.04.006","article-title":"Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction","volume":"215","author":"Shovlin","year":"2016","journal-title":"Int J Cardiol"},{"issue":"10","key":"2022041419424788200_B42","doi-asserted-by":"crossref","first-page":"E591","DOI":"10.1002\/ajh.24832","article-title":"Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia","volume":"92","author":"Kasthuri","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2022041419424788200_B43","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2018.205682","article-title":"Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia","volume":"104","author":"Thielemans","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2022041419424788200_B44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ajmg.1320320302","article-title":"Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population","volume":"32","author":"Plauchu","year":"1989","journal-title":"Am J Med Genet"},{"issue":"2","key":"2022041419424788200_B45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2004.07.050","article-title":"Pica and food craving in patients with iron-deficiency anemia: a case-control study in France","volume":"118","author":"Kettaneh","year":"2005","journal-title":"Am J Med"},{"issue":"11","key":"2022041419424788200_B46","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1503\/cmaj.110950","article-title":"Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial","volume":"184","author":"Vaucher","year":"2012","journal-title":"CMAJ"},{"issue":"5","key":"2022041419424788200_B47","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2005.11.1104","article-title":"The diagnosis and treatment of iron deficiency and its potential relationship to hair loss","volume":"54","author":"Trost","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"2S-2","key":"2022041419424788200_B48","doi-asserted-by":"crossref","first-page":"676S","DOI":"10.1093\/jn\/131.2.676S","article-title":"Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship","volume":"131","author":"Haas","year":"2001","journal-title":"J Nutr"},{"issue":"4","key":"2022041419424788200_B49","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/thoraxjnl-2011-201076","article-title":"Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia","volume":"67","author":"Livesey","year":"2012","journal-title":"Thorax"},{"issue":"5","key":"2022041419424788200_B50","first-page":"1031","article-title":"Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism","volume":"98","author":"Shovlin","year":"2007","journal-title":"Thromb Haemost"},{"key":"2022041419424788200_B51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fgene.2015.00101","article-title":"Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia","volume":"6","author":"Shovlin","year":"2015","journal-title":"Front Genet"},{"issue":"12","key":"2022041419424788200_B52","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00277-012-1553-8","article-title":"Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation","volume":"91","author":"Edwards","year":"2012","journal-title":"Ann Hematol"},{"issue":"9","key":"2022041419424788200_B53","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMc1213554","article-title":"Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia","volume":"368","author":"Devlin","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2022041419424788200_B54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13023-019-1179-1","article-title":"Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia","volume":"14","author":"Shovlin","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2022041419424788200_B55","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13023-019-1278-z","article-title":"Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group","volume":"14","author":"Gaetani","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2022041419424788200_B56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/21678707.2017.1353417","article-title":"Current and emerging pharmacotherapies for hereditary hemorrhagic telangiectasia","volume":"5","author":"Albi\u00f1ana","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"issue":"10","key":"2022041419424788200_B57","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/14728222.2017.1365839","article-title":"Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia [published correction appears in Expert Opin Ther Targets. 2017;21(10):995.]","volume":"21","author":"Ruiz-Llorente","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"2022041419424788200_B58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-0037-1615709","article-title":"Hemostatic effects of tamoxifen in hereditary hemorrhagic telangiectasia","volume":"85","author":"Zacharski","year":"2001","journal-title":"Thromb Haemost"},{"issue":"4","key":"2022041419424788200_B59","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00005537-200404000-00021","article-title":"Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia","volume":"114","author":"Jameson","year":"2004","journal-title":"Laryngoscope"},{"issue":"12","key":"2022041419424788200_B60","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1017\/S0022215100081597","article-title":"The effect of oestrogen on the nasal respiratory mucosa. An experimental histopathological and histochemical study","volume":"89","author":"Helmi","year":"1975","journal-title":"J Laryngol Otol"},{"issue":"1","key":"2022041419424788200_B61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13023-020-01453-1","article-title":"Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding","volume":"15","author":"Beckman","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2022041419424788200_B62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","article-title":"Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia","volume":"14","author":"Buscarini","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2022041419424788200_B63","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.mayocp.2020.03.001","article-title":"Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy","volume":"95","author":"Albitar","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2022041419424788200_B64","article-title":"An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia [published online ahead of print 20 May 2020]","author":"Al-Samkari","journal-title":"Haemophilia"},{"issue":"1","key":"2022041419424788200_B65","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","article-title":"Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers","volume":"14","author":"Al-Samkari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2022041419424788200_B66","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1002\/ajh.25563","article-title":"Octreotide for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia: A prospective case series","volume":"94","author":"Kroon","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2022041419424788200_B67","doi-asserted-by":"crossref","first-page":"e00088","DOI":"10.14309\/crj.0000000000000088","article-title":"Successful Treatment of Hereditary Hemorrhagic Telangiectasia With Octreotide","volume":"6","author":"Houghton","year":"2019","journal-title":"ACG Case Rep J"},{"key":"2022041419424788200_B68","doi-asserted-by":"crossref","first-page":"bcr1120103534","DOI":"10.1136\/bcr.11.2010.3534","article-title":"Rendu-Osler disease: treatment with oestrogen\/progestagen versus octreotide","volume":"2011","author":"Jeanneret","year":"2011","journal-title":"BMJ Case Rep"},{"issue":"5","key":"2022041419424788200_B69","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/mol.110.067447","article-title":"Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-\u03b21 signaling in endothelial cells","volume":"79","author":"Albi\u00f1ana","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"2","key":"2022041419424788200_B70","doi-asserted-by":"crossref","first-page":"2045894018805406","DOI":"10.1177\/2045894018805406","article-title":"Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension","volume":"9","author":"Sommer","year":"2019","journal-title":"Pulm Circ"},{"key":"2022041419424788200_B71","first-page":"629","article-title":"Tacrolimus treatment for two rare complications caused by hereditary haemorrhagic telangiectasia: A description of two cases","volume":"22","author":"Hosman","year":"2019","journal-title":"Angiogenesis"},{"issue":"2","key":"2022041419424788200_B72","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI127425","article-title":"Correcting Smad1\/5\/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models","volume":"130","author":"Ruiz","year":"2020","journal-title":"J Clin Invest"},{"issue":"3","key":"2022041419424788200_B73","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/lt.21990","article-title":"Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study","volume":"16","author":"Dupuis-Girod","year":"2010","journal-title":"Liver Transpl"},{"issue":"17","key":"2022041419424788200_B74","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1161\/CIRCULATIONAHA.118.036952","article-title":"Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model","volume":"139","author":"Crist","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"2022041419424788200_B75","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1038\/ncomms13650","article-title":"PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia","volume":"7","author":"Ola","year":"2016","journal-title":"Nat Commun"},{"issue":"22","key":"2022041419424788200_B76","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.210.210","article-title":"Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study [abstract]","volume":"128","author":"Samour","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2022041419424788200_B77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"key":"2022041419424788200_B78","first-page":"21932","article-title":"Nintedanib as a novel treatment option in hereditary haemorrhagic telangiectasia","volume":"2017","author":"Kovacs-Sipos","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"7","key":"2022041419424788200_B79","first-page":"301","article-title":"[Intravenous iron-dextran: therapeutic and experimental possibilities]","volume":"100","author":"Ganzoni","year":"1970","journal-title":"Schweiz Med Wochenschr"},{"issue":"1","key":"2022041419424788200_B80","first-page":"49","article-title":"Percutaneous left atrial appendage closure-An alternative strategy for anticoagulation in atrial fibrillation and hereditary hemorrhagic telangiectasia?","volume":"5","author":"Vorselaars","year":"2015","journal-title":"Cardiovasc Diagn Ther"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/137\/7\/888\/1888295\/bloodbld2020008739c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/137\/7\/888\/1888295\/bloodbld2020008739c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T19:44:23Z","timestamp":1649965463000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/7\/888\/474132\/Hereditary-hemorrhagic-telangiectasia-systemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,2,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008739","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}